The Neurodegenerative Alzheimer's Disease: A Critical Analysis | Chapter 8 | Research Developments in Medicine and Medical Science Vol. 3

Researchers studied how dementia affects around 45 million people globally, according to estimates. Alzheimer's disease (AD) is the leading cause of dementia, accounting for 60-80% of cases. It affects an estimated 5.8 million Americans aged 65 and more. In 2020, it is anticipated that payments for healthcare and hospice services for Americans 65 and older with dementia will total $305 billion. Physostigmine is an AChE inhibitor that was initially discovered from Calabar beans in 1864.

Alzheimer's disease (AD) is the leading cause of death in people aged 65 and older in the United States, according to a report by the Alzheimer's Association. More than 90% of all patients experience restlessness, anxiety, depression, delusions, dementia, motor abnormality, irritability, sleep problems, hunger disorders, or poor impulse control. MicroRNAs, that influence gene expression post-transcriptionally, have been used to diagnose Alzheimer's disease. Alzheimer's disease is the most advanced type of dementia in the globe. The National Institute of Neurological Disorders and Stroke (NINCDS-ADRDA) has issued a new set of criteria for the diagnosis of Alzheimer's disease. 

a β  fragments and NFTs are significant markers for Alzheimer's disease. Dementia, dependency, and disability all have social consequences. Alzheimer's patients may benefit from drugs that help them maintain their freedom and optimize their functionality. These deposits arise as a result of native proteins folding incorrectly. Disinterest, anxiousness, nervousness, distress, delusions, 

$\mathrm{<a\; href="https://en.wikipedia.org/wiki/dementia"\; style="box-sizing:\; border-box;\; user-select:\; text\; !important;"><span\; style="color:\; \#375c7b;\; text-decoration-line:\; none;">dementia</span></a>,\; motor\; activity\; abnormality,\; irritation,\; abnormal\; sleep\; problems,\; eating\; disorders,\; or\; poor\; impulse\; control\; affect\; Alzheimer\text{'}s\; patients.<o:p></o:p>}$

Alzheimer's disease pathology may be slowed by the use of combination treatment and future tau pathology medicines.

$$

It is critical to diagnose AD early. Dementia can determine by an EEG test. The electric impulses of cortical neurons are read by EEG, which shows the function of the brain. AD can be treated with a variety of criteria, including programs, bodily fluids, and imaging studies. AchE inhibitors and many therapies are used for the treatment of AD. Gene therapy is a process that has a lot of attention in Studies. The basic method was to introduce a gene that produces an enzyme or growth factor that is reparative. Depending on the target ailment, the method of gene transfer and in-vivo vs ex-vivo treatment differs.

Author(s) Details:

Krishna Babu Ojha,
Amardeep College of Pharmacy, Firozabad, India.

Ravi Rajput,
Amardeep College of Pharmacy, Firozabad, India.

Anurag,
Amardeep College of Pharmacy, Firozabad, India.

Soumyadip Mukherjee,
Amardeep College of Pharmacy, Firozabad, India.

Abhishek Kashyap,
Amardeep College of Pharmacy, Firozabad, India.

Yadav Rupali Vinod,
Pranveer Singh Institute of Technology, Kanpur, India.

Please see the link here: https://stm.bookpi.org/RDMMS-V3/article/view/9918

The Reactivity Sites of Amyloid -Peptides A40 and A42 in Alzheimer's Disease: Computational Prediction | Chapter 6 | Challenges and Advances in Chemical Science Vol. 2

 Alzheimer's disease is a degenerative nervous system ailment caused by extracellular senile plaques. Extracellular senile plaques are usually made up of 40-42 residues of -peptides, which are amino acid-containing polypeptides. The Theory of Chemical Reactivity, MEDT (Molecular Electron Density Theory), and Conceptual DFT were used to find descriptors that allowed QM:MM calculations with the ONIOM methodology to predict the sites of reactivity of the Alzheimer amyloid β-peptides Aβ40 and Aβ42.

Author (S) Details

Juan Frau
Departament de Química, Universitat de les Illes Balears, 07122 Palma de Mallorca, Spain.

Daniel Glossman-Mitnik
Departamento de Medio Ambiente y Energía, Centro de Investigación en Materiales Avanzados, Laboratorio Virtual Nanocosmos, Chihuahua, Chih 31136, Mexico.

View Book :- https://stm.bookpi.org/CACS-V2/article/view/2655

Study on Unexpected Capability of Melanin to Split the Water Molecule and the Alzheimer’s Disease | Chapter 8 | Highlights on Medicine and Medical Research Vol. 9

Because the incidence and prevalence of the three major causes of blindness had not altered in the previous forty years, we initiated a study in 1990. Twelve years later, we learned that the human retina's principal source of energy is water, not ATP. This holds true for the entire human body. Water is the primary source of energy. We were unaware of eukaryotic cells' extraordinary capacity to break or dissociate the water molecule because it requires 2000°C to dissociate water in a laboratory environment, and it was previously thought that only plants could do so. this is it. Water isn't just for washing away filth and toxins; it's also a cleaning and a fundamental solvent that we consume on a daily basis. As our bodies dissolve the water molecule, hydrogen may supply energy to cells (Hydrogen is the energy carrier that Nature uses the most). Water is our primary source of energy. We'd have to eat between 50 and 170 kilograms (110 and 374 lbs.) every day if our bodies couldn't get enough energy from water. When a systemic breakdown occurs in any system, we must immediately suspect energy. Generalized failures include Parkinson's disease and Alzheimer's disease. That clarifies why it isn't. Patients rarely improve considerably when the human photosynthesis process is pharmacologically stimulated. Keep in mind that energy is required not only for the brain to expand and perform functions, but also to preserve its structure and structure. The most abundant source of energy for human cells is hydrogen. Low levels of water dissociation over time in Alzheimer's disease reflect a persistent energy shortage, which can show in a variety of ways as the disease progresses.

Author (s) Details

Maria del Carmen Arias-Esparza
Human Photosynthesis Study Center, Research, Development and Innovation Department, Aguascalientes, Mexico.

Ruth Isabel Solís Arias
Human Photosynthesis Study Center, Research, Development and Innovation Department, Aguascalientes, Mexico.

Paola Eugenia Solís Arias
Human Photosynthesis Study Center, Research, Development and Innovation Department, Aguascalientes, Mexico.

Martha Patricia Solís Arias
Human Photosynthesis Study Center, Research, Development and Innovation Department, Aguascalientes, Mexico.

Arturo Solís-Herrera
Human Photosynthesis Study Center, Research, Development and Innovation Department, Aguascalientes, Mexico.

View Book : - https://stm.bookpi.org/HMMR-V9/article/view/1028